GSK Plans Major R&D Overhaul

Published on: 

Pharma major aims to focus majority of R&D capital into priority therapy areas and plans to cut approximately 30 R&D programs.

At a meeting held in London on July 26, 2017 for its second-quarter earnings, GlaxoSmithKline (GSK) outlined a series of new priorities for the company, including a major overhaul of its R&D programs. Under new leadership with Emma Walmsely, who took over as CEO in April 2017, GSK’s top priority is to improve the pharmaceuticals business, particularly by strengthening the pipeline.

A key near-term focus is to maximize value from new products and three other significant new-launch opportunities: Shingrix, a potential new vaccine for shingles; Closed Triple, a new 3-in-1 respiratory medicine; and two new drug regimens in HIV.

For its pharmaceuticals pipeline, GSK has developed a priority list of assets in which to invest, but the list can change depending on the data that reads out. The company is also aiming to deploy over time 80% of its pharmaceuticals R&D capital to priority assets in two current therapy areas: respiratory and HIV/infectious diseases; and two potential areas: oncology and immuno-inflammation. Significant data are expected from these priority assets over the next three years, which will be used to inform R&D investment decisions and how best to generate value from these assets. GSK also expects to pursue disciplined business development to augment its early-stage pipeline in these priority areas.

As part of its efforts to prioritize and allocate resources in R&D, GSK is terminating development programs that are unlikely to generate sufficient returns. GSK has so far made decisions to terminate, partner, or divest more than 30 pre-clinical and clinical programs. The company has also undertaken a strategic review of its rare diseases unit and is now considering options for future ownership of these assets.

In addition, GSK is taking steps to improve the partnership between R&D and its commercial organization as well as its governance around pipeline decision-making. To achieve this, the company has established a new development advisory board and a new board scientific committee.

Advertisement

Beyond pharmaceuticals, GSK aims to realize further benefits from its newly scaled consumer healthcare and vaccines businesses. It is also aiming to increase investment flexibility with a series of measures to improve cash generation and clearer capital allocation priorities, according to the company.

Source: GlaxoSmithKline